<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705989</url>
  </required_header>
  <id_info>
    <org_study_id>IM014-001</org_study_id>
    <nct_id>NCT02705989</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics,&#xD;
      and pharmacodynamics following single and multiple ascending oral doses of BMS-986195 in&#xD;
      healthy subjects, and to assess the relative bioavailability of two formulations of&#xD;
      BMS-986195 with or without food.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2016</start_date>
  <completion_date type="Actual">August 16, 2017</completion_date>
  <primary_completion_date type="Actual">August 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single oral dose of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>Up to 8 days during and after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of multiple oral doses of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests</measure>
    <time_frame>Up to 21 days during and after last dose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">439</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose of BMS-986195 or Placebo matching BMS-986195</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relative Bioavailability with Food Effects (Open Label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986195</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Relative Bioavailability with Food Effects (Open Label)</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>Japanese-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index(BMI) of 18 to 32 kilograms/meter^2&#xD;
&#xD;
          -  Healthy male and female, first generation Japanese with confirmed paternal and&#xD;
             maternal Japanese ancestry, 18-55 years old, whose residency outside of Japan does not&#xD;
             exceed 10 years with a BMI of 18-30 kilograms/meter^2 inclusive.&#xD;
&#xD;
          -  Women must not be pregnant or breastfeeding&#xD;
&#xD;
          -  Women of Childbearing Potential (WOCBP) must agree to follow instructions for&#xD;
             method(s) of contraception for the duration of treatment with study drug plus 14 days&#xD;
             or longer if required.&#xD;
&#xD;
          -  Males who are sexually active with WOCBP must agree to follow instructions for&#xD;
             method(s) of contraception for the duration of treatment with study drug plus 14 days&#xD;
             or longer if required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Known or suspected autoimmune disorder, including but not limited to rheumatoid&#xD;
             arthritis, fibromyalgia, systemic lupus erythematosis, polymyalgia rheumatica, giant&#xD;
             cell arteritis, Behcet's disease, dermatomyositis, multiple sclerosis, moderate to&#xD;
             severe asthma, any autoimmune vasculitis, autoimmune hepatitis, or any other active&#xD;
             autoimmune disease for which a subject requires medical follow-up or medical treatment&#xD;
&#xD;
          -  Any history of known or suspected congenital or acquired immunodeficiency state or&#xD;
             condition that would compromise the subject's immune status (example: history of&#xD;
             splenectomy)&#xD;
&#xD;
          -  Presence of any factors that would predispose the subject to develop infection e.g.,&#xD;
             rectal fissures, poor dentition, open skin lesions, and presence of preexisting skin&#xD;
             conditions that increase risks for injection site complications e.g. Behcet's Disease,&#xD;
             Psoriasis, pustular dermatoses&#xD;
&#xD;
          -  Any history or risk for tuberculosis (TB)&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Branebrutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

